MAPT and Alzheimer disease: Oligomer levels detected by the current assays tend to be higher in CSF from subjects with MCI than in AD or age-matched control subjects, but there was considerable overlap between the levels found in all three groups, whereas the accepted AD CSF biomarkers Aβ42, tau and p-tau clearly distinguished AD and MCI from controls.